BY:

PALAK BHARDWAJ
GAURAV SATIA
VARUN KALIA
Global Presence
•Top 10 Global Generic Company
•Sales in Over 125 Countries
•2008 Revenue: $ 1.7 Billion
•80 % International; 20% India
•Ground Presence in 49 Countries
•Global Team with Global Mindset
•Over 12,000 Employees; Over 50
Nationalities
Ranbaxy success on global scale

li a n c es
A l
and n
i siti o
acq u

Team
building
Investment in
R&D
 BUSINESS MODEL

Global Reach Product Portfolio

Business
Model
Therapeutic drug
Research Development
ERA OF GENERICS…………….

e n t c o p y
b i o e q ui l v
r i c i s a l l y
Gene n d r u g ,l e g a
rm u l a t i o te d a f t e r
of fo a n d m a r k e
n u f a c t u r e o v at o r
m a o f a n i n n
t E x p i r y
paten
drug.
Growth of Global Market of generics 1998 – 2008
Turn over in USD Billion

78
80
70
70
60
60
50 44.8

40
30
20
10 3.2 3.5
0
1998 1999 2000 2006 2007 2008

6
 GENERIC DRUGS
growth of generics
the growth of Generics, especially since 70’s, been facilitated by :
• Increase of life-expectancy and increase of chronic diseases of elder
population,
• Slow temp of innovations and decrease of number of new molecules,
• deficit of social and medical insurance funds, health sector reforms aimed
to cut-down drug and therapy spending,
WHO recommends usage of Generics to make essential drugs more
accessible to the people, especially the developing countries.
 Growth of generics
in Billion USD

180 168
160 147
140 130
113
120
100
100 87
80
60
40
20
0
2009 2010 2011 2012 2013 2014
PROJECTED TO GROW AT 11-13% OVER
NEXT 3-5 YEARS
• Population Dynamics • High Disease
Burden

- Large Population
base diabetes,AIDS…
Fastest Growing
- Increasing life
expentancy

rural india
and growth rates in Reimbursement
Improving access avenues,Literacy rate

• Increased Healthcare • Increasing

Access Capacity To
spend
 RANBAXY REACH IN CHINA……

Rannbaxy Laboratories has sold its Chinese

JV, Ranbaxy Guangzhou China Limited
(RGCL)  
Gareth Macdonald, 05-Jan-2010
This transaction is part of Ranbaxy’s endeavour
to develop a new business model for China
which entails the marketing of value added
pharmaceutical formulations and the
consolidation of manufacturing operations, for
cost synergies.”
 CONT………………USA

$258 Billion market(in 2005).

50% of global sales $558 billion.

FACTS:-
- Lipitor earned $36 million revenues.
- Ranbaxy launched donepezil 5mg/10mg
 Y OU
HA NK
T